The Great Imposter: Three Cases of Inflammatory Bowel Disease Associated with Innate Immune Defects
DOI:
https://doi.org/10.52787/agl.v56i3.597Keywords:
Inflammatory bowel disease, inborn errors of immunity, monogenic disease, pediatrics, IPEX syndrome, XIAP deficiencyAbstract
Pediatric inflammatory bowel disease associated with inborn errors of immunity represents a diagnostic and therapeutic challenge, particularly in cases of early-onset, severe disease, extraintestinal manifestations, or refractoriness to treatment. We present three pediatric cases with an aggressive clinical course, multisystemic involvement, and an inadequate response to multiple therapeutic lines of therapy, in whom the persistent presence of warning signs prompted genetic testing. In one of these patients, exome sequencing identified a pathogenic variant in FOXP3, confirming the diagnosis of IPEX syndrome. In the other two patients, who were siblings, an alteration in XIAP was identified, consistent with a diagnosis of X-linked lymphoproliferative syndrome type 2. In the index patient with XIAP deficiency, the initial exome sequencing did not identify any causative variants. Subsequently, genome sequencing established the molecular diagnosis, which subsequently led to the cascade diagnosis of his sibling. These cases highlight the importance of early recognition of phenotypes suggestive of monogenic disease, maintaining diagnostic suspicion despite initially negative genetic test results, and conducting a timely multidisciplinary evaluation. Identification of an underlying inborn error of immunity can substantially modify the therapeutic approach, allow for the consideration of potentially curative options such as hematopoietic stem cell transplantation, and facilitate family genetic counseling.
References
-1. Poddar U, Aggarwal A, Jayalakshmi K, Sarma MS, Srivastava A, Rawat A, et al. Higher Prevalence of Monogenic Cause Among Very Early Onset Inflammatory Bowel Disease in Children: Experience From a Tertiary Care Center From Northern India. Inflammatory Bowel Diseases. el 3 de octubre de 2023;29(10):1572-8. DOI:10.1093/ibd/izac254
-2. Ouahed J, Spencer E, Kotlarz D, Shouval DS, Kowalik M, Peng K, et al. Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies. Inflammatory Bowel Diseases. el 12 de mayo de 2020;26(6):820-42. DOI:10.1093/ibd/izz259
-3. Arai K. Very Early-Onset Inflammatory Bowel Disease: A Challenging Field for Pediatric Gastroenterologists. Pediatr Gastroenterol Hepatol Nutr. 2020;23(5):411. DOI:10.5223/pghn.2020.23.5.411
-4. Hall CHT, De Zoeten EF. Understanding very early onset inflammatory bowel disease (VEOIBD) in relation to inborn errors of immunity. Immunological Reviews. marzo de 2024;322(1):329-38. DOI:10.1111/imr.13302
-5. Van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, et al. The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update. Journal of Crohn’s and Colitis. el 1 de febrero de 2021;15(2):171–94. DOI: 10.1093/ecco-jcc/jjaa161
-6. Chapuy L, Leduc B, Godin D, Damphousse A, Patey N, Dal Soglio D, et al. Phenotype and outcomes of very early onset and early onset inflammatory bowel diseases in a Montreal pediatric cohort. Front Pediatr. el 4 de abril de 2023;11:1157025. DOI:10.3389/fped.2023.1157025
-7. Nambu R, Warner N, Mulder DJ, Kotlarz D, McGovern DPB, Cho J, et al. A Systematic Review of Monogenic Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology. abril de 2022;20(4):e653-63. DOI:10.1016/j.cgh.2021.03.021
-8. Crowley E, Warner N, Pan J, Khalouei S, Elkadri A, Fiedler K, et al. Prevalence and Clinical Features of Inflammatory Bowel Diseases Associated With Monogenic Variants, Identified by Whole-Exome Sequencing in 1000 Children at a Single Center. Gastroenterology. junio de 2020;158(8):2208-20. DOI: 10.1053/j.gastro.2020.02.023
-9. Baccarella A, Patel T, Conrad MA, Macchi M, Boyer B, Pickering O, et al. Outcomes of Allogeneic Hematopoietic Stem Cell Transplant in Monogenic Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology. noviembre de 2025;23(12):2242-2252.e4. DOI:10.1016/j.cgh.2025.03.018
-10. Li QQ, Zhang HH, Dai SX. New Insights and Advances in Pathogenesis and Treatment of Very Early Onset Inflammatory Bowel Disease. Front Pediatr. el 1 de marzo de 2022;10:714054. DOI:10.3389/fped.2022.714054
-11. Consonni F, Ciullini Mannurita S, Gambineri E. Atypical Presentations of IPEX: Expect the Unexpected. Front Pediatr. el 5 de febrero de 2021;9:643094. DOI:10.3389/fped.2021.643094
-12. Barzaghi F, Amaya Hernandez LC, Neven B, Ricci S, Kucuk ZY, Bleesing JJ, et al. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. Journal of Allergy and Clinical Immunology. marzo de 2018;141(3):1036-1049.e5. DOI:10.1016/j.jaci.2017.10.041
-13. Aguilar C, Lenoir C, Lambert N, Bègue B, Brousse N, Canioni D, et al. Characterization of Crohn disease in X-linked inhibitor of apoptosis–deficient male patients and female symptomatic carriers. Journal of Allergy and Clinical Immunology. noviembre de 2014;134(5):1131-1141.e9. DOI:10.1016/j.jaci.2014.04.031
-14. Speckmann C, Lehmberg K, Albert MH, Damgaard RB, Fritsch M, Gyrd-Hansen M, et al. X-linked inhibitor of apoptosis (XIAP) deficiency: The spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. Clinical Immunology. octubre de 2013;149(1):133-41. DOI:10.1016/j.clim.2013.07.004
-15. Kelsen JR, Sullivan KE, Rabizadeh S, Singh N, Snapper S, Elkadri A, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Evaluation and Management for Patients With Very Early-onset Inflammatory Bowel Disease. J pediatr gastroenterol nutr. marzo de 2020;70(3):389-403. DOI:10.1097/MPG.0000000000002567
-16. Charbit-Henrion F, Parlato M, Hanein S, Duclaux-Loras R, Nowak J, Begue B, et al. Diagnostic Yield of Next-generation Sequencing in Very Early-onset Inflammatory Bowel Diseases: A Multicentre Study. Journal of Crohn’s and Colitis. el 29 de agosto de 2018;12(9):1104-12. DOI:10.1093/ecco-jcc/jjy068
-17. Sánchez Hernández DP, Cuadros Mendoza CA, Sammache K, Nieto J, Wilchez Luna A, Ramírez Urrego LC, et al. Enfermedad inflamatoria de inicio muy temprano (VEO-IBD) en Colombia: estudio multicéntrico [Póster]. Póster presentado en: VI Congreso PANCCO y V Congreso Colombiano GECCOL. 2026; Cartagena, Colombia.
-18. Ono S, Takeshita K, Kiridoshi Y, Kato M, Kamiya T, Hoshino A, et al. Hematopoietic Cell Transplantation Rescues Inflammatory Bowel Disease and Dysbiosis of Gut Microbiota in XIAP Deficiency. The Journal of Allergy and Clinical Immunology: In Practice. octubre de 2021;9(10):3767-80. DOI:10.1016/j.jaip.2021.05.045
-19. Marsh RA, Rao K, Satwani P, Lehmberg K, Müller I, Li D, et al. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood. el 7 de febrero de 2013;121(6):877-83. DOI:10.1182/blood-2012-06-432500
-20. Arnold DE, Nofal R, Wakefield C, Lehmberg K, Wustrau K, Albert MH, et al. Reduced-Intensity/Reduced-Toxicity Conditioning Approaches are Tolerated in XIAP Deficiency but Patients Fare Poorly with Acute GVHD. J Clin Immunol. enero de 2022;42(1):36-45. DOI:10.1007/s10875-021-01103-6
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Diana Paola Sánchez Hernández, Sara Vallejo Tamayo

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.










